Regulated information
Waregem (Belgium)/Rotterdam (Netherlands)1, 30 April 2015
Fagron announces today that there are no changes in the Guarantor List in accordance with the Guarantee Declaration dated 12 June 2012 regarding the € 225,000,000 4.75% Bond with maturity date 2 July 2017.
The list of Guarantors, in accordance with Article 10.4 of the Guarantee Declaration, is available at investors.fagron.com.
In accordance with Condition 10 (b) of the Bonds a new Compliance Certificate is published. This Compliance Certificate is available at investors.fagron.com.
In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.
Fagron profile
Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding. Fagron offers Fagron Compounding Services, Fagron Trademarks and Fagron Compounding Essentials to pharmacies and hospitals in 32 countries worldwide. Pharmaceutical compounding is an essential part of pharmaceutical care that enables prescribers and pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron’s own R&D department consists of 45 researchers and more than 300 pharmacists who are working continually on developing new concepts, vehicles and formulations to treat an increasing number of patients with tailor-made compounded medication.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.
For further information
Marieke Palstra
Global Investor Relations Director
Tel. +31 88 33 11 213
marieke.palstra@fagron.com
investors.fagron.com
1 This press release was sent out by Fagron NV and Fagron BV.
Please open the link below for the press release: